Relevant bibliographies by topics / HIV-infections HIV-infections HIV-1 Antiretroviral therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'HIV-infections HIV-infections HIV-1 Antiretroviral therapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'HIV-infections HIV-infections HIV-1 Antiretroviral therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "HIV-infections HIV-infections HIV-1 Antiretroviral therapy"

1

&NA;. "Tipranavir enhances antiretroviral therapy for HIV-1 infections." Inpharma Weekly &NA;, no. 1550 (August 2006): 16. http://dx.doi.org/10.2165/00128413-200615500-00040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kline, Erik R., and Roy L. Sutliff. "The Roles of HIV-1 Proteins and Antiretroviral Drug Therapy in HIV-1-Associated Endothelial Dysfunction." Journal of Investigative Medicine 56, no. 5 (June 1, 2008): 752–69. http://dx.doi.org/10.1097/jim.0b013e3181788d15.

Full text
Abstract:
Since the emergence of highly active antiretroviral therapy (HAART), human immunodeficiency virus-1 (HIV-1)-infected patients have demonstrated dramatic decreases in viral burden and opportunistic infections, and an overall increase in life expectancy. Despite these positive HAART-associated outcomes, it has become increasingly clear that HIV-1 patients have an enhanced risk of developing cardiovascular disease over time. Clinical studies are instrumental in our understanding of vascular dysfunction in the context of HIV-1 infection. However, most clinical studies often do not distinguish whether HIV-1 proteins, HAART, or a combination of these 2 factors cause cardiovascular complications. This review seeks to address the roles of both HIV-1 proteins and antiretroviral drugs in the development of endothelial dysfunction because endothelial dysfunction is the hallmark initial step of many cardiovascular diseases. We analyze recentin vitroandin vivostudies examining endothelial toxicity in response to HIV-1 proteins or in response to the various classes of antiretroviral drugs. Furthermore, we discuss the multiple mechanisms by which HIV-1 proteins and HAART injure the vascular endothelium in HIV-1 patients. By understanding the molecular mechanisms of HIV-1 protein- and antiretroviral-induced cardiovascular disease, we may ultimately improve the quality of life of HIV-1 patients through better drug design and the discovery of new pharmacological targets.
APA, Harvard, Vancouver, ISO, and other styles
3

Concha, Mauricio, and Alejandro Rabinstein. "Central Nervous System Opportunistic Infections in HIV-1 Infection." CNS Spectrums 5, no. 4 (April 2000): 43–60. http://dx.doi.org/10.1017/s1092852900013110.

Full text
Abstract:
AbstractNeurologic disease is commonly encountered in the population infected with human immunodeficiency virus type 1 (HIV-1). Although HIV-1 is responsible for many of these neurologic complications, other organisms will affect the nervous system as the immune deficiency state progresses. With the wide use of potent antiretroviral therapy, the mortality from and incidence of opportunistic infections (OIs) among persons with advanced HIV-1 infection has decreased. Nevertheless, these diseases are still seen frequently, especially among those with limited access to new antiretroviral therapies. Therefore, it remains important to recognize the most common OIs of the central nervous system (CNS) as well as primary CNS lymphoma, which will be the focus of this review.
APA, Harvard, Vancouver, ISO, and other styles
4

Permanyer, Marc, Ester Ballana, Alba Ruiz, Roger Badia, Eva Riveira-Munoz, Encarna Gonzalo, Bonaventura Clotet, and José A. Esté. "Antiretroviral Agents Effectively Block HIV Replication after Cell-to-Cell Transfer." Journal of Virology 86, no. 16 (June 13, 2012): 8773–80. http://dx.doi.org/10.1128/jvi.01044-12.

Full text
Abstract:
Cell-to-cell transmission of HIV has been proposed as a mechanism contributing to virus escape to the action of antiretrovirals and a mode of HIV persistence during antiretroviral therapy. Here, cocultures of infected HIV-1 cells with primary CD4+T cells or lymphoid cells were used to evaluate virus transmission and the effect of known antiretrovirals. Transfer of HIV antigen from infected to uninfected cells was resistant to the reverse transcriptase inhibitors (RTIs) zidovudine (AZT) and tenofovir, but was blocked by the attachment inhibitor IgGb12. However, quantitative measurement of viral DNA production demonstrated that all anti-HIV agents blocked virus replication with similar potency to cell-free virus infections. Cell-free and cell-associated infections were equally sensitive to inhibition of viral replication when HIV-1 long terminal repeat (LTR)-driven green fluorescent protein (GFP) expression in target cells was measured. However, detection of GFP by flow cytometry may incorrectly estimate the efficacy of antiretrovirals in cell-associated virus transmission, due to replication-independent Tat-mediated LTR transactivation as a consequence of cell-to-cell events that did not occur in short-term (48-h) cell-free virus infections. In conclusion, common markers of virus replication may not accurately correlate and measure infectivity or drug efficacy in cell-to-cell virus transmission. When accurately quantified, active drugs blocked proviral DNA and virus replication in cell-to-cell transmission, recapitulating the efficacy of antiretrovirals in cell-free virus infections andin vivo.
APA, Harvard, Vancouver, ISO, and other styles
5

Duffalo, Melody L. "Fungal Opportunistic Infections in HIV Disease." Journal of Pharmacy Practice 19, no. 1 (February 2006): 17–30. http://dx.doi.org/10.1177/0897190005284095.

Full text
Abstract:
Fungal pathogens can lead to many of the complications seen in advanced HIV disease and are commonly identified in HIV-infected populations with decreased immune function. Common fungal organisms affecting individuals with AIDS include Cryptococcus neoformans, various Candida species, and Histoplasma capsulatum. While infection with these organisms can be fatal, appropriate identification and management of the condition can result in reduced mortality and the opportunity for effectivemanagement of HIV disease with highly active antiretroviral therapy. This article describes the clinical presentation and treatment of 3 fungal infections common in the immunocompromised individual with AIDS. Current antifungal therapy for themanagement of these infections is discussed. In addition, the role of newer antifungal agents in the setting of these conditions is reviewed.
APA, Harvard, Vancouver, ISO, and other styles
6

Purdy, Bonnie D. "Management and Prevention of Opportunistic Infections in the HIV-Infected Patient." Journal of Pharmacy Practice 13, no. 6 (December 2000): 475–98. http://dx.doi.org/10.1106/jdyc-jyvc-xjaa-lj1f.

Full text
Abstract:
With the introduction of potent antiretroviral therapy, the incidence of opportunistic infections (OIs) as well as death has dramatically decreased since 1996. Opportunistic infections are seen mainly in three groups: (1) newly diagnosed patients not receiving antiretroviral therapy and presenting with an OI, (2) patients nonadherent to antiretroviral and OI treatment regimens or (3) patients whose antiretroviral therapy has failed. This article will review the most common opportunistic infections (OIs) seen in the HIV-infected individual and their treatment. The current guidelines for the prophylaxis against these OIs will also be discussed.
APA, Harvard, Vancouver, ISO, and other styles
7

Adhikary, Rishi Rajat, Prachi More, and Rinti Banerjee. "Smart nanoparticles as targeting platforms for HIV infections." Nanoscale 7, no. 17 (2015): 7520–34. http://dx.doi.org/10.1039/c5nr01285f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Thomas, Dia-Jeanette. "Mycobacterial Diseases in HIV-Positive Patients." Journal of Pharmacy Practice 19, no. 1 (February 2006): 10–16. http://dx.doi.org/10.1177/0897190005284100.

Full text
Abstract:
Mycobacterial infections comprise the largest group of opportunistic infections in the HIV-infected population. The incidence of these and other opportunistic infections has declined significantly since the introduction of highly active antiretroviral therapy. Mortality from these illnesses has decreased as optimal combinations of antibiotics were discovered. Despite these facts, mycobacterial infections still pose a major threat to AIDS patients, particularly in underserved populations. The most common mycobacterial infections found in HIV-infected individuals are Mycobacterium tuberculosis, Mycobacterium avium intracellulare, and Mycobacterium kansasii, although other nontuberculous mycobacteria have been isolated. While established guidelines have made the task of preventing and treating opportunistic infections easier, resistance, toxicity, adherence, and drug interactions remain barriers to providing optimal therapy.
APA, Harvard, Vancouver, ISO, and other styles
9

Zimina, Vera, Svetlana Degtyareva, Elena Beloborodova, Julia Klimova, and Alexey Kravchenko. "Concurrent treatment of HIV, disseminated Mycobacterium avium complex and HCV-infection." Folia Medica 63, no. 4 (August 31, 2021): 586–90. http://dx.doi.org/10.3897/folmed.63.e56124.

Full text
Abstract:
Patients with HIV-infection diagnosed at late stages usually have significant immunosuppression and demand simultaneous antiretroviral therapy and treatment of opportunistic infections. The presence of HCV coinfection makes treatment even more challenging because of possible adverse effects and drug-drug interactions. HCV cure in such clinical situations not only prevents fibrosis progression, but can also enhance virologic and/or immunologic response to antiretrovirals and thus effective treatment of opportunistic infections. Thorough consideration of all existing diseases and drug interactions of the combined therapy makes simultaneous treatment of HIV, chronic hepatitis C, and opportunistic infections not only possible but the best way to improve outcomes in a complex clinical situation.
APA, Harvard, Vancouver, ISO, and other styles
10

Lavender, Kerry J., Kathrin Gibbert, Karin E. Peterson, Erik Van Dis, Sandra Francois, Tyson Woods, Ronald J. Messer, et al. "Interferon Alpha Subtype-Specific Suppression of HIV-1 InfectionIn Vivo." Journal of Virology 90, no. 13 (April 20, 2016): 6001–13. http://dx.doi.org/10.1128/jvi.00451-16.

Full text
Abstract:
ABSTRACTAlthough all 12 subtypes of human interferon alpha (IFN-α) bind the same receptor, recent results have demonstrated that they elicit unique host responses and display distinct efficacies in the control of different viral infections. The IFN-α2 subtype is currently in HIV-1 clinical trials, but it has not consistently reduced viral loads in HIV-1 patients and is not the most effective subtype against HIV-1in vitro. We now demonstrate in humanized mice that, when delivered at the same high clinical dose, the human IFN-α14 subtype has very potent anti-HIV-1 activity whereas IFN-α2 does not. In both postexposure prophylaxis and treatment of acute infections, IFN-α14, but not IFN-α2, significantly suppressed HIV-1 replication and proviral loads. Furthermore, HIV-1-induced immune hyperactivation, which is a prognosticator of disease progression, was reduced by IFN-α14 but not IFN-α2. Whereas ineffective IFN-α2 therapy was associated with CD8+T cell activation, successful IFN-α14 therapy was associated with increased intrinsic and innate immunity, including significantly higher induction of tetherin and MX2, increased APOBEC3G signature mutations in HIV-1 proviral DNA, and higher frequencies of TRAIL+NK cells. These results identify IFN-α14 as a potent new therapeutic that operates via mechanisms distinct from those of antiretroviral drugs. The ability of IFN-α14 to reduce both viremia and proviral loadsin vivosuggests that it has strong potential as a component of a cure strategy for HIV-1 infections. The broad implication of these results is that the antiviral efficacy of each individual IFN-α subtype should be evaluated against the specific virus being treated.IMPORTANCEThe naturally occurring antiviral protein IFN-α2 is used to treat hepatitis viruses but has proven rather ineffective against HIV in comparison to triple therapy with the antiretroviral (ARV) drugs. Although ARVs suppress the replication of HIV, they fail to completely clear infections. Since IFN-α acts by different mechanism than ARVs and has been shown to reduce HIV proviral loads, clinical trials are under way to test whether IFN-α2 combined with ARVs might eradicate HIV-1 infections. IFN-α is actually a family of 12 distinct proteins, and each IFN-α subtype has different efficacies toward different viruses. Here, we use mice that contain a human immune system, so they can be infected with HIV. With this model, we demonstrate that while IFN-α2 is only weakly effective against HIV, IFN-α14 is extremely potent. This discovery identifies IFN-α14 as a more powerful IFN-α subtype for use in combination therapy trials aimed toward an HIV cure.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "HIV-infections HIV-infections HIV-1 Antiretroviral therapy"

1

Russell, Rodney S. "The influence of HIV-1 proviral burden on disease progression and response to antiretroviral therapy." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0015/MQ55539.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hejdeman, Bo. "Studies on medical and immunological interventions in HIV-1 infection /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7140-019-2/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fernandez, Sonia. "CD4⁺ T-cell deficiency and dysfunction in HIV patients receiving combination antiretroviral therapy /." Connect to this title, 2006. http://theses.library.uwa.edu.au/adt-WU2007.0120.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

De, Milito Angelo. "Immune activation during HIV-1 infection : implication for B cell dysfunctions and therapy monitoring /." Stockholm, 2002. http://diss.kib.ki.se/2002/91-7349-170-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Srasuebkul, Preeyaporn Public Health &amp Community Medicine Faculty of Medicine UNSW. "Evaluating monitoring strategies, short-term disease progression and rate of treatment change in HIV-infected patients commencing antiretroviral therapy in the Asia-Pacific region." Publisher:University of New South Wales. Public Health & Community Medicine, 2008. http://handle.unsw.edu.au/1959.4/41673.

Full text
Abstract:
This thesis assesses factors associated with a number of short and long-term outcomes in HIV-infected patients receiving antiretroviral treatment in Asia. Analyses in this thesis were based on two cohorts of HIV-infected patients; The Treat Asia HIV Observational Database (TAHOD), a multi-centre prospective observational cohort from countries in Asia-Pacific region, and the HIV Netherlands Australia Thailand (HIV-NAT) collaboration cohort, a cohort of patients treated with antiretroviral treatments at HIV-NAT in Bangkok, Thailand. We examined factors associated with time to immunological failure endpoints, such as CD4≤ 200 cells/??L, CD4≤ 100 cells/ ??L, and CD4 return to baseline, and with the virological failure endpoint, detectable viral load defined as a value greater than 500 copies/mL. Multivariate Cox proportional hazard models were used. Results showed that CD4 count at baseline and changes in CD4 strongly predicted immunological failure. For virological failure, detectable viral load at baseline was the strongest predictor. As a step to developing simplified monitoring strategies, in which patients with a low risk of failure could have their monitoring CD4 count and viral load tests deferred, we developed predictive models for each immunological and virological failure endpoint. Models were developed on the HIV-NAT cohort, and validated on the independent TAHOD cohort. For predictive models, the complementary log-log transformation for each endpoint was fitted appropriate to the interval censored nature of the data. To assess goodness-of-fit, cut-offs were defined for the predicted risks that separated patients from low risk to high risk. Overall, the observed versus expected failures from HIV-NAT data agreed quite well across all endpoints, probably reflecting that the HIV-NAT database was the data we built the models upon. Not only did these models fit the HIV-NAT database well, they also discriminated patients from low to high risk groups. When we validated models with TAHOD data, the observed and expected failures agreed well only in the model for CD4 count return to baseline. For most of the endpoints, the predictive models overestimated the number of failures, with predicted values larger than observed. However, the proportions of failures were lowest in the low risk group and highest in the high risk group, indicating that our models did discriminate between patients at high and low risk, and that the predictive models might still be of use for the purpose of simplified monitoring strategies. With CD4 count and viral load monitoring tests now comprising a large component of the cost of HIV treatment in resource limited settings, we developed and assessed a simplified monitoring strategy that aimed to reduce the numbers of monitoring tests performed. The predictive models developed earlier were used to calculate the probabilities of failure in TAHOD patients. We assumed that patients would have their CD4 and viral load assessments annually, at baseline and at one year, predicted risk of failure at ensuing clinical visits, week 12, 24 and 36. For patients at low predicted risk of failure at ensuing clinical visits, we assessed the effect of deferring monitoring tests, both in terms of blood tests avoided, and in terms of delaying detection of failure in some patients. A number of levels for the predicted risk of failure that lead to deferral of testing were evaluated. The results suggested that predicted probabilities of failure of 10% - 20% gave the best results across all failure endpoints. These cut-offs could save a median of 598 (51.6%) (range 37 (2.6%)_-1,218 (81.9%) ) blood tests over the first year of treatment, but would fail to detect 29 (18%) (range 10 (7.4%) - 128 (39.3%) ) failures. The median time from failure to detection in those patients who did fail and had deferred monitoring tests was 28 weeks. Rates of antiretroviral treatment change in TAHOD were examined. We identified patterns and factors associated with the rate of treatment change. Median time to the first treatment change was 3.2 years. Factors predicting rate of treatment change in TAHOD were treatment combination, being on second or third combination, number of drugs available in each site and being an injecting drug user. The overall rate of treatment change in TAHOD was 29 per 1OO-person-year. Around 30% of patients stopped their treatment due to adverse events. These rates of treatment change are lower than have been seen in patients in western countries. This may be due to patients in developing countries having access to fewer antiretroviral drugs than patients in developed countries.
APA, Harvard, Vancouver, ISO, and other styles
6

Behbahani, Homira. "Immune dysregulation in HIV-1 infected lymphoid tissue /." Stockholm, 2002. http://diss.kib.ki.se/2002/91-7349-193-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fernandez, Sonia. "CD4? T-cell deficiency and dysfunction in HIV patients receiving combination antiretroviral therapy." University of Western Australia. School of Surgery and Pathology, 2007. http://theses.library.uwa.edu.au/adt-WU2007.0120.

Full text
Abstract:
[Truncated abstract] Failure to fully reconstitute the immune system is a common clinical problem in HIV patients who were severely immunodeficient before responding to combination antiretroviral therapy (CART). This can manifest as a deficiency in the number or function of CD4+ T-cells and occurs most often in patients who had a nadir CD4+ T-cell count below 100/μl when CART was commenced. Observational studies of large cohorts of HIV patients, such as the D:A:D study, have demonstrated that patients with low CD4+ T-cell counts have increased rates of death compared with patients who have normal CD4+ T-cell counts. Furthermore, individual case studies suggest that impaired recovery of pathogen-specific immune responses during CART is associated with opportunistic infections or disease progression. This thesis addresses possible causes of deficiencies in CD4+ T-cell number or function in HIV patients who were very immunodeficient prior to treatment and are responding (virologically) to CART. Firstly, the role of the thymus in producing naive CD4+ T-cells and the effects of persistent immune activation on the recovery of CD4+ T-cell numbers were assessed in patients with either low or high CD4+ T-cell counts after long-term CART. ... Proportions of antigen presenting cell (APC) subpopulations were examined in HIV patients with low or high CMV-specific CD4+ T-cell responses after long-term CART. HIV patients had significantly lower proportions of plasmacytoid dendritic cells (pDC) than HIV-negative controls. Furthermore, the proportions of pDC were positively correlated with CMV-specific CD4+ T-cell responses in HIV patients. Proportions of myeloid dendritic cells (mDC) were significantly higher in HIV patients than controls, and were also increased in patients with low CMV-specific CD4+ T-cell responses. Proportions of M-DC8+ dendritic cells or CD14+ monocytes did not differ between patients and controls, nor were they associated with CMV-specific CD4+ T-cell responses. Quantitation of cytokine (interferon-α, tumour necrosis factor-α, interleukin (IL) -12, IL-23, IL-15, IL-18 and IL-10) mRNA in unstimulated, purified populations of the APC described above revealed few significant differences between patients with low or high CD4+ T-cell IFN-γ responses to CMV. The only notable difference was the slight elevation of IL-15 mRNA levels in patients compared to controls. Since patients in the high responder group had the highest levels of IL-15 mRNA, this association may reflect the anti-apoptotic properties of IL-15. These studies provide valuable insights into the causes of persistent CD4+ T-cell deficiency and dysfunction in HIV patients on CART and may lead to better monitoring and treatments.
APA, Harvard, Vancouver, ISO, and other styles
8

Parathyras, John Burns. "Molecular genetic analysis of human immunodeficiency virus antiretroviral therapy response in South Africa : a pharmacogenetics study." Thesis, Link to the online version, 2007. http://hdl.handle.net/10019/453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lindström, Anna. "Resistance to antiviral drugs in HIV and HBV /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-239-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Atlas, Ann. "Immunological and virological response to antiretroviral treatment (art) in patients infected with different HIV-1genetic subtypes /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-645-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "HIV-infections HIV-infections HIV-1 Antiretroviral therapy"

1

P, Flaherty John, and Taiwo Babafemi O, eds. Contemporary diagnosis and management of HIV/AIDS infections. 3rd ed. Newtown, Pa: Handbooks in Health Care Co., 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

P, Flaherty John, ed. Contemporary diagnosis and management of HIV/AIDS infections. 2nd ed. Newtown, Pa: Handbooks in Health Care, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bartlett, John G. 2007 Medical management of HIV infection. 2nd ed. Baltimore, MD: Johns Hopkins Medicine, Health Publishing Business Group, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

HIV and liver disease. New York: Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Subdivision, Namibia Ministry of Health and Social Services Directorate of Special Programmes Response Monitoring &. Evaluation. Report on the 2010 HIV drug resistance survey: Population-based monitoring of HIV drug resistance emerging during treatment and related programme factors in sentinel antiretroviral therapy sites in Namibia. Windhoek: Directorate of Special Programmes, Response Monitoring & Evaluation Subdivision, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kalanzi, Dorothy J. AIDS crisis control in Uganda: The use of HAART. Amherst, NY: Cambria Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

World Health Organization (WHO). Monitoring equity in access to AIDS treatment programmes: A review of concepts, models, methods and indicators. Geneva: World Health Organization, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

World Health Organization. Regional Office for South-East Asia. Strategic considerations for scaling up antiretroviral therapy for children living with HIV/AIDS in South-East Asia: Guidelines for programme managers. New Delhi: World Health Organization, Regional Office for South-East Asia, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Namibia. Ministry of Health and Social Services. Directorate of Special Programmes. Response Monitoring & Evaluation Subdivision. Report of the 2006 Namibia HIV Drug Sensitivity Survey. Windhoek, Namibia: Directorate of Special Programmes, Division Expanded National HIV/AIDS Coordination, Subdivision: Response Monitoring & Evaluation, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Swan, Tracy. Care and treatment for hepatitis C and HIV coinfection: Expanding access through the Ryan White CARE Act. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "HIV-infections HIV-infections HIV-1 Antiretroviral therapy"

1

Jäger, H. "Nebenwirkungen antiretroviraler Therapie." In HIV-Infekt, 226–29. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59683-4_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Arendt, G. "Antiretrovirale Therapie (ART) und Nervensystem." In HIV-Infekt, 201–6. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59683-4_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gartner, Manfred. "Antiretrovirale HIV-Therapie." In Opiatabhängigkeit, 93–99. Vienna: Springer Vienna, 2003. http://dx.doi.org/10.1007/978-3-7091-3796-3_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Grosch-Woerner, J. "Antiretrovirale Therapie bei Schwangeren: Konsensus-Statement." In HIV-Infekt, 211–18. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59683-4_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shire, Norah J. "Antiretroviral Therapy and Hepatotoxicity." In HIV and Liver Disease, 163–70. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1712-6_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Haire, Bridget. "Providing Universal Access While Avoiding Antiretroviral Resistance: Ethical Tensions in HIV Treatment." In Ethics and Drug Resistance: Collective Responsibility for Global Public Health, 37–54. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-27874-8_3.

Full text
Abstract:
Abstract The provision of effective antiretroviral therapy is an ethical imperative, and global access to antiretroviral drugs is an important aspect of this. The other less recognised aspect of effective HIV management is in ensuring that HIV does not become resistant to the drugs used in treatment (and increasingly also in prevention), as multi-drug resistant HIV poses a major threat to the sustainability of current responses to HIV control. In resource-constrained environments, the rapid scale up of access to life-saving anti-HIV treatment was achieved using a public health approach that standardised antiretroviral regimens, minimised laboratory monitoring, and devolved responsibilities from clinicians where necessary. In recent years demand for antiretroviral treatment has increased due to new understandings of the clinical importance of early treatment, but global investment has declined. Exponential growth of the population using antiretrovirals without careful monitoring increases the risk of significant antiretroviral drug resistance. In this chapter, I consider the example of single-drug interventions to prevent parent-to-child HIV transmission, and how the implementation of that strategy increased health risks for mothers. I argue that while global antiretroviral scale up must continue, laboratory monitoring at individual and national levels needs to improve to maintain treatment effectiveness, and protocols for moving people from failing regimens need to be strengthened.
APA, Harvard, Vancouver, ISO, and other styles
7

Bock, J., O. Jacobsen, D. Riemer, M. Hautzinger, and L. C. Escobar-Pinzón. "Compliance mit antiretroviraler Therapie: Eine Standortbestimmung." In HIV-Infekt, 710–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59683-4_127.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Staszewski, S., and V. Miller. "Antiretrovirale Therapie: Wie beginnen und wie fortsetzen?" In HIV-Infekt, 20–31. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60722-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wintergerst, U. "Die antiretrovirale Therapie des HIV-infizierten Kindes." In HIV-Infekt, 283–88. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59683-4_50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rockstroh, J. K. "Antiretrovirale Therapie (ART) mit nukleosidalen reverse Transkriptaseinhibitoren (NRT)." In HIV-Infekt, 207–10. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59683-4_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "HIV-infections HIV-infections HIV-1 Antiretroviral therapy"

1

Grewal, Ramandip, Vanessa Allen, Ahmed M. Bayoumi, Sandra L. Gardner, Rupert Kaul, Tony Mazzulli, Frank Mcgee, et al. "P2.36 Sexually transmitted co-infections and the effect of drug use on risk of virologic failure among hiv-positive men on antiretroviral therapy." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Caulk, Alexander W., and Rudolph L. Gleason. "Treatment With Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Leads to Increase of Carotid Intima-Media Thickness in Mice." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14744.

Full text
Abstract:
Since the advent of highly active antiretroviral therapy (HAART), patients infected with human immunodeficiency virus-1 (HIV-1) are living longer lives. However, HIV-1-positive (HIV-1+) patients are now experiencing many non-AIDS related comorbidities including myocardial infarction, atherosclerotic lesions, and other preclinical markers of atherosclerosis including increased carotid intima-media thickness (cIMT), arterial stiffness, and impaired flow-mediated dilation (FMD). Studies have implicated the virus, the treatment, or both in the progression of these co-morbidities, causing the exact mechanisms of cardiovascular disease progression to remain unclear.
APA, Harvard, Vancouver, ISO, and other styles
3

Hansen, Laura, Manu O. Platt, Roy L. Sutliff, and Rudolph L. Gleason. "The Mechanical and Structural Changes in Murine Arteries due to the Antiretroviral Drug Azidothymidine (AZT)." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80799.

Full text
Abstract:
With over 33 million people infected with the human immunodefeciency virus (HIV-1), HIV-1 and autoimmune deficiency syndrome (AIDS) is a worldwide epidemic [1]. However, the development and widespread use of highly active antiretroviral therapy (HAART) has helped transform HIV-1 infection from a terminal disease leading to AIDS to a manageable chronic condition. With the increase in life expectancy, a new set of non-AIDS related complications has emerged including dyslipidemia, lipodystrophy, insulin resistance, diabetes mellitus, and cardiovascular disease (CVD) specifically high risks for myocardial infarction[2] and increased incidence of atherosclerosis [3]. Additionally, patients exhibit markers of subclinical atherosclerosis including endothelial dysfunction [4], carotid artery intima-media thickening [5], and arterial stiffening [4, 6].
APA, Harvard, Vancouver, ISO, and other styles
4

Mustafa, Fadhil Ilham, Nurfitri Bustamam, and Andri Pramesyanti. "Association between Compliance Level on Fixed-Dose Combination Antiretroviral Drug and CD4 Level among HIV Patients." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.02.03.

Full text
Abstract:
Background: People living with HIV / AIDS (PLWHA) have weak immune systems and are prone to infection. Therefore, PLWHA must take antiretroviral (ARV) to maintain their immunity. This study aimed to determine the relationship between the level of adherence to taking ARV fixed-dose combination (FDC) drugs and CD4 levels of HIV patients. Subjects and Method: This was a cross-sectional study conducted at Pengayoman Cipinang Hospital, Indonesia, in 2018. Total of 91 HIV patient over 17 years of age, had or had received FDC ARV therapy for at least 1 year, and did not experience drug-induced hepatitis were enrolled in this study. The dependent variable was CD4 level. The independent variable was level of adherence to taking ARV fixed-dose combination (FDC). The data were taken from the Voluntary Counseling and Testing Poli Pengayoman Cipinang Hospital. This study used secondary data from the Overview of HIV Care and ARV Therapy. The data were analyzed using Chi-square. Results: A total of 65.93% HIV patients had a good level of medication adherence and 79.12% had an increase of CD4 levels. There was a significant relationship between adherence to taking FDC ARV drugs and CD4 levels (OR = 6.50; 95% CI = 2.15 to 19.62; p<0.001), and it was statistically significant. Conclusion: There is a significant relationship between the level of adherence to taking FDC ARV drugs and CD4 levels. Therefore, patients must receive education and support to improve adherence to taking ARV drugs. Keywords: antiretroviral, CD4, fixed-dose combination, adherence to taking medication, people with HIV / AIDS Correspondence: Fadhil Ilham Mustafa. Faculty of Medicine, Universitas Pembangunan Nasional Veteran, Jakarta. Jl. RS Fatmawati, Pondok Labu, South Jakarta. Email: fadhilimn@gmail.com. Mobile: 081283681755. DOI: https://doi.org/10.26911/the7thicph.02.03
APA, Harvard, Vancouver, ISO, and other styles
5

Hansen, Laura, Manu Platt, Roy L. Sutliff, and Rudolph L. Gleason. "The Mechanical and Structural Effects of HIV Proteins on Murine Carotid Arteries." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53693.

Full text
Abstract:
Acquired immunodeficiency syndrome (AIDS) is considered a global epidemic with over 65 million people worldwide infected with the HIV-1 virus, the causative agent [1]. The development of highly active antiretroviral therapy (HAART) has significantly increased the life expectancy of people infected with the virus by slowing the progression to the development of AIDS. However, the treatment has also led to the emergence of early onset cardiovascular complications including myocardial infarction [2] and atherosclerotic lesions [3], as well as subclinical markers of atherosclerosis including increased carotid artery intima-media thickness [4], increased arterial stiffness [5–6], and endothelial dysfunction [6]. It appears that HAART and HIV-1-infection are independent risk factors for the development of atherosclerosis in adults [7]; however, the mechanism of disease progression remains unclear. There is a pressing need to identify mechanisms of early on-set cardiovascular disease associated with HIV-1 infection and HAART and to identify therapeutic strategies to reduce cardiovascular disease in HIV patients. The overall goal of this study is to test the hypothesis that over-expression of HIV proteins will lead to alterations in the biomechanical properties of large arteries.
APA, Harvard, Vancouver, ISO, and other styles
6

Raimundo, Silvia Martorano, Ezio Venturino, Hyun Mo Yang, Theodore E. Simos, George Psihoyios, and Ch Tsitouras. "A Mathematical Model of Antiretroviral Therapy Evaluation for HIV Type 1." In NUMERICAL ANALYSIS AND APPLIED MATHEMATICS: International Conference on Numerical Analysis and Applied Mathematics 2009: Volume 1 and Volume 2. AIP, 2009. http://dx.doi.org/10.1063/1.3241398.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lucht, Lorrie, Mark P. Oleksiuk, Matthew R. Gingo, Cathy J. Kessinger, Barbara Rissler, Joseph K. Leader, david Claman, et al. "Pulmonary Function In HIV-Infected And HIV-Negative Persons In The Era Of Antiretroviral Therapy." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a6264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Qin, S., J. Cyktor, S. M. Nouraie, M. Fitzpatrick, C. J. Kessinger, R. DeSensi, L. Huang, J. Mellors, and A. M. Morris. "Association Among Levels of HIV-1 Persistence, Systemic Inflammation and Pulmonary Dysfunction in Persons Living with HIV on Antiretroviral Therapy." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6519.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

GILADA, ISHWAR, and T. GILADA. "PREVENTION OF HIV-1 INFECTION WITH EARLY ANTIRETROVIRAL THERAPY: TREATMENT AS PREVENTION—TASP." In International Seminar on Nuclear War and Planetary Emergencies — 46th Session. WORLD SCIENTIFIC, 2014. http://dx.doi.org/10.1142/9789814623445_0030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Baraldi, Robert, Karissa Cross, Christina McChesney, Laura Poag, Emma Thorpe, Kevin B. Flores, and H. T. Banks. "Uncertainty quantification for a model of HIV-1 patient response to antiretroviral therapy interruptions." In 2014 American Control Conference - ACC 2014. IEEE, 2014. http://dx.doi.org/10.1109/acc.2014.6858714.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "HIV-infections HIV-infections HIV-1 Antiretroviral therapy"

1

Djimeu, Eric W., and Eleanor G. Dickens. Treatment as prevention: a replication study on early antiretroviral therapy initiation and HIV-1 transmission. International Initiative for Impact Evaluation (3ie), June 2020. http://dx.doi.org/10.23846/rps0024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Samuels, Fiona, Joseph Simbaya, Avina Sarna, Scott Geibel, Phillimon Ndubani, and Jolly Kamwanga. Engaging communities in supporting HIV prevention and adherence to antiretroviral therapy in Zambia. Population Council, 2008. http://dx.doi.org/10.31899/hiv12.1001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Andersson, Rune. Family support is important for adherence to antiretroviral therapy among HIV positive mothers. Science Repository OÜ, March 2019. http://dx.doi.org/10.31487/j.cmr.2018.01.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Djimeu, Eric W. When to start ART? A replication study of timing of antiretroviral therapy for HIV-1-associated Tuberculosis. International Initiative for Impact Evaluation (3ie), January 2018. http://dx.doi.org/10.23846/rps0014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tao, Zhuang, Xiaojie Huang, Ying LIU, Jipeng Dong, Yang Zhao, and Jian Wang. Adherence to Antiretroviral Therapy of HIV/AIDS patients in China: A system review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2020. http://dx.doi.org/10.37766/inplasy2020.6.0044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sarna, Avina, and Scott Kellerman. Looking back, moving forward: Access to antiretroviral therapy for HIV infected adults and children in developing countries: Horizons Studies, 2002 to 2008. Population Council, 2010. http://dx.doi.org/10.31899/hiv10.1007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Galarraga, Omar, David Salkever, Judith Cook, and Stephen Gange. An Instrumental Variable Evaluation of Antidepressant Use on Employment Among HIV-Infected Women Using Highly-Active Antiretroviral Therapy in the United States: 1996-2004. Cambridge, MA: National Bureau of Economic Research, October 2006. http://dx.doi.org/10.3386/w12619.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Adherence to Antiretroviral Therapy in Adults: A Guide for Trainers. Population Council, 2004. http://dx.doi.org/10.31899/hiv15.1000.

Full text
Abstract:
Over the last five years, there has been a rapid change in treatment strategies for HIV infection. With the advent of newer antiretrovirals, treatment has moved from mono-therapy and bi-therapy to triple drug therapy or Highly Active Antiretroviral Therapy. One of the foremost concerns of ARV programs is the ability of people living with HIV/AIDS to maintain near perfect adherence over the long term. To achieve the goal of antiretroviral therapy (ART), undetectable levels of the virus in the blood, patients are required to maintain more than 90–95% adherence. Adherence is defined as a patient’s ability to follow a treatment plan, take medications at prescribed times and frequencies, and follow restrictions regarding food and other medications. This Adherence Training Manual was developed by the Horizons Program of the Population Council for the Antiretroviral Therapy Program in Mombasa, Kenya. It was designed for health workers including physicians, clinical officers, and adherence nurse counselors in ARV programs. It consists of four modules to be conducted over four sessions, which can be conducted as part of a comprehensive ART training program.
APA, Harvard, Vancouver, ISO, and other styles
9

Starting antiretroviral therapy immediately after HIV diagnosis reduces transmission of the virus. National Institute for Health Research, January 2018. http://dx.doi.org/10.3310/signal-000530.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'HIV-infections HIV-infections HIV-1 Antiretroviral therapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography